Shares of Ocugen, Inc. (NASDAQ:OCGN) reached at $8.74 price level during last trade its distance from 20 days simple moving average was -10.25%, and its distance from 50 days simple moving average was 67.99% while it has a distance of 464.24% from the 200 days simple moving average. Ocugen (NASDAQ:OCGN) is a latecomer to the coronavirus vaccine race. It recently gained rights to co-commercialize Bharat Biotech’s vaccine candidate in the U.S. In this Motley Fool Live video, recorded on Feb. 26, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss Ocugen’s partnership with the India-based company — and whether the companies can potentially carve out a share of the U.S. market.
Investing legends and Motley Fool Co-founders David and Tom Gardner just revealed what they believe are the 10 best stocks for investors to buy right now… and Ocugen, Inc. wasn’t one of them.
The online investing service they’ve run for nearly two decades, Motley Fool Stock Advisor, has beaten the stock market by over 4X.* And right now, they think there are 10 stocks that are better buys.
Corinne Cardina: A lot of the companies we’ve talked about, we’ve been talking about them for quite a while, for some of them, a little under a year. But just this month, a new name has popped up on the vaccine horizon and that is Ocugen. This is a company that is developing gene therapy for eye diseases. But it said it’s bringing a vaccine candidate to the FDA. It’s doing a deal with an Indian company called Bharat Biotech, and it’s going to commercialize Bharat’s vaccine in the U.S. What should investors know about this latecomer to the vaccine race? Do you think it could carve out a share of the U.S. market?
Adria Cimino: Well, I think it’s going to be difficult. I think that Covaxin is already authorized in India, we don’t have phase 3 data yet on it. But supposedly it produces a broad immune response beyond the spike and that means that it could handle strains. So that sounds good and if that turns out to be the fact in the phase 3 trials, great. My one concern though is Ocugen has this deal for co-commercialization in the U.S. — and that’s where we now have enough vaccine ordered for this year. I think it’s going to be really difficult. I think there’s going to be a lot of competition in the U.S. right away. Unless the vaccine is a whole lot better than rivals, it’s really going to face some difficult competition. I would say for now remain cautious on this stock and just keep watching and see. It might be some long-term opportunity, but right now remain cautious.
Past 5 years growth of OCGN observed at 50.60%, and for the next five years the analysts that follow this company are expecting its growth at 0. The average true range (ATR) is a measure of volatility introduced by Welles Wilder in his book, “New Concepts in Technical Trading Systems.” The true range indicator is the greatest of the following: current high less the current low, the absolute value of the current high less the previous close and the absolute value of the current low less the previous close. The average true range is a moving average, generally 14 days, of the true ranges.
The stock has a market cap of $1.69B with 188.03M shares outstanding, of which the float was 156.67M shares. Analysts consider this stock active, since it switched Trading volume reached 33,732,296 shares as compared to its average volume of 90.01M shares. The Average Daily Trading Volume (ADTV) demonstrates trading activity related to the liquidity of the security. When Ave Volume tends to increase, it shows enhanced liquidity.
But when Ave Volume is lower, the security will tend to be cheap as people are not as keen to purchase it. Hence, it might have an effect on the worth of the security. OCGN’s relative volume was 0.34. Relative volume is a great indicator to keep a close eye on, but like most indicators it works best in conjunction with other indicators and on different time frames. Higher relative volume you will have more liquidity in the stock which will tighten spreads and allow you to trade with more size without a ton of slippage.
Important Technical Indicators Analysis Report and Volatility Measures:
Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. Beta is used in the capital asset pricing model (CAPM), which calculates the predictable return of an asset based on its beta and predictable market returns. Beta is also known as the beta coefficient.
A beta of 1 indicates that the security’s price moves with the market. A beta of less than 1 means that the security is theoretically less volatile than the market. A beta of greater than 1 indicates that the security’s price is theoretically more volatile than the market. After a recent check, beta value for this stock comes out to be 4.52. A statistical measure of the dispersion of returns (volatility) for OCGN producing salvation in Investors mouth, it has week volatility of 22.23% and for the month booked as 29.70%. Regardless of which metric you utilize, a firm understanding of the concept of volatility and how it is measured is essential to successful investing. A stock that maintains a relatively stable price has low volatility. When investing in a volatile security, the risk of success is increased just as much as the risk of failure.
The volatility value is used by the investors for various reasons and purposes in measuring the fundamental price change and the rate of variation in OCGN’s price. The ART is a specific type of indicator, which is capable of weighing up stock volatility in the financial markets effectively.
Ocugen, Inc. has an average true range (ATR) of 2.20. Other technical indicators are worth considering in assessing the prospects for EQT. OCGN’s price to sales ratio for trailing twelve months was 39576.08 and price to book ratio for most recent quarter was 87.40, whereas price to cash per share for the most recent quarter was 88.31. The Company’s price to free cash flow for trailing twelve months was 0. Its quick ratio for most recent quarter was 4.80. Analysts mean recommendation for the stock was 2.20. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Should You Go With High Insider Ownership?
Many value investors look for stocks with a high percent of insider ownership, under the theory that when management are shareholders, they will act in its own self interest, and create shareholder value in the long-term. This aligns the interests of shareholders with management, thus benefiting everyone. While this sounds great in theory, high insider ownership can actually lead to the opposite result, a management team that is unaccountable because they can keep their jobs under almost any circumstance.
Ocugen, Inc.‘s shares owned by insiders remained 3.26%, whereas shares owned by institutional owners are 7.70%.
Where Do Relative Strength Index (RSI) Stands?
Perhaps, it is one of the most important indicators, because it is used in the technical analysis of the stock in the money market. The relative strength index (RSI) is claimed to depict the latest and past performances of the stock market, based upon the ending price volumes of the current trading period. The RSI is characterized as a momentum oscillator, evaluating the speed and scale of directional price shifts. The momentum exemplifies both rising and falling rates of the Price in the stock market. Using RSI, you can calculate momentum as the percentage of elevated closes to reduced closes. But if the stocks have experienced optimistic changes rapidly, then it might have an increased RSI than stocks. So, it might cause negative changes in the market.
The RSI index is largely used by traders on a 14-day time period and is evaluated on a range from 0 to 100, along with both high and low volumes marked at 70 and 30, correspondingly. Both the shorter and longer timeframes are used by the traders for shorter and longer purposes. It further adds high and low ranges like from 80 to 20 and from 90 to 10. This trend takes place less repeatedly.
However, it represents stronger momentum in the market. In the meantime, the Accenture plc’s 14-day RSI was settled at 52.67. All in all, the trends of the stock market were shifting slowly but surely.
Meanwhile, OCGN traded under umbrella of Healthcare sector, the stock was traded -53.44% ahead of its 52-week high and 5041.18% beyond its 52-week low. So, both the price and 52-week high indicators would give you a clear-cut picture to evaluate the price direction.